Royalty Report: Drugs, Disease, Therapeutic – Collection: 256262

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Fibrosis
  • Drug Discovery
  • Delivery
  • Respiratory
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 256262

License Grant
The Licensors grant an exclusive license in the Territory under the Licensed Patents and Information for all  purposes, including without limitation, to develop, use, make, have made, import, have imported, export, have exported, offer for sale, have sold and sell Licensed Products.
License Property
The patents are for anti-fibrotic uses of Pirfenidon.  

'Licensed Patents' means that certain U.S. Patent No. 5,310,562 with respect to the anti-fibrotic uses of Pirfenidon.

Field of Use
The field of use is for the therapeutic treatment of a specific fibrotic human disease.
The Licensee licensed the rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis.
Fibrosis, or the accumulation of extracellular matrix molecules that make up scar tissue, is a common feature of chronic tissue injury. Pulmonary fibrosis, renal fibrosis, and hepatic cirrhosis are among the more common fibrotic diseases, which in aggregate represent a huge unmet clinical need.

IPSCIO Record ID: 294019

License Grant
Licensor hereby grant to Licensee an exclusive (even to Licensor), royalty-bearing, freely sublicenseable license in the Territory under the Licensed Patents and Information for  all purposes, including without limitation, to develop, use, make, have made, import, have imported, export, have exported, offer for sale, have sold and sell Licensed Products.
License Property
Licensed Product means a product that utilizes or incorporates a Valid Claim for the therapeutic treatment of a specific fibrotic human disease, which product has been approved after the Effective Date for the therapeutic treatment of such specific fibrotic human disese by the United States Food and Drug Administration (FDA) and/or any Regulatory Agenciies through the granting of a New Drug Application (NDA) or equivalent foreign approval document.

Licensed Patents means that certain U.S. Patent No. 5,310,562; and all corresponding foreign patent applications and patents throughout the Territory, including any and all divisions, re-issues, re-examinations, renewals, continuations and substitutes in whole or in part of such patents and patent applications in the Territory with respect to the anti-fibrotic  uses of Pirfenidone; and all Patents defined. The Licensed Patents shall specifically exclude U.S. Patent No. 5,962,478 titled Tumor Necrosis Factor Alpha.
5,310,562 – Composition and method for reparation and prevention of fibrotic lesions

Patents means all of Licensors (a) anti-fibrotic, Pirfenidone patent applications heretofore or hereafter filed or having legal force in any country including without limitation divisionals, continuations, continuation-in-part and provisional applications; (b) issued, unexpired anti-fibrotic Pirfenidone patents in any country, including utility, model and design patents and certificates of invention; and (c) substitutions, extensions, reissues, renewals, and supplementary protection certificates with respect to any such issued patents. For clarity, such patent applications and patents shall include those owned, as well as those controlled with the right to grant licenses, by any of Licensors. The Patents shall not include patent applications and patents to the extent claiming uses of Pirfenidone other than for anti-fibrotic uses, nor uses of compounds for anti-fibrotic applications other than Pirfenidone.

Field of Use
This agreement pertains to the drug industry relating to products potentially useful in the prevention, mitigation and treatment of fibrotic and other diseases.

Fibrosis, also known as Fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue.

IPSCIO Record ID: 26673

License Grant
The University grants to the Licensee and exclusive, worldwide License with the right to grant sublicenses, in all fields of use, to make, have made, import, use, market, offer for sale, and sell Licensed Products and to practice Licensed Processes.

Pursuant to this Agreement, we will use our best efforts to commercialize COPREXATM for the therapeutic uses embodied in the issued patent and pending patent application.

COPREXATM has been designated by the FDA as an orphan drug for the treatment of Wilson’s disease patients presenting with neurologic complications.

License Property
Licensed Products means any products comprises or all uses of U.S. Patent No. 6,855,340, corresponding international applications, and a related corresponding patent application that relates to various uses of anticopper therapeutics, including COPREXATM, to treat inflammatory and fibrotic diseases.

Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This is as opposed to formation of fibrous tissue as a normal constituent of an organ or tissue. Scarring is confluent fibrosis that obliterates the architecture of the underlying organ or tissue.

Field of Use
COPREXATM is an oral, small-molecule, anti-copper agent that is highly specific for lowering the level of free copper in serum, the most toxic form of copper in the body. Thus, it may be suited for the treatment of central nervous system (CNS) diseases in which abnormal serum and CNS copper homeostasis are implicated.

IPSCIO Record ID: 304025

License Grant
The Company and University entered into an exclusive, worldwide license agreement for the use of certain patents and technology relating to avß1 compound in fibrosis indications.
License Property
avß1 is a integrins that is being developed for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC and for the treatment of liver fibrosis.

TGF-ß signaling is the central pathway by which fibrosis occurs. TGF-ß is a signaling molecule that is secreted by cells as an inactive complex and stored in the extra-cellular matrix. In healthy tissue, TGF-ß is transiently activated in response to tissue injury, resulting in collagen production and, ultimately, healing of the tissue. In fibrosis, however, TGF-ß becomes continuously activated, leading to excess collagen production, sometimes even in the absence of the initial tissue injury, which leads to thickening and stiffening of tissues. TGF-ß can be activated by a class of cell surface proteins known as integrins. In certain fibrotic diseases such as IPF and PSC, the integrins avß6 and avß1, which are normally expressed at very low levels, have been shown to be upregulated and to cause the continuous activation of TGF-ß. We believe that, by inhibiting fibrosis-specific TGF-ß activators such as avß6 and avß1, it may be possible to block abnormal TGF-ß activation in fibrotic tissues without affecting TGF-ß signaling in healthy tissues.

Field of Use
Licensee is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.  The initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ß.

Fibrosis, also known as fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue.

IPSCIO Record ID: 263060

License Grant
In this Agreement, the Licensee expanded the scope of the license agreement with the Licensor, who prior to 2015 was Parent of Licensee, for rights to develop and commercialize pulsed nitric oxide for idiopathic pulmonary fibrosis to include patients with Pulmonary Fibrosis (PH-PF).
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices, based on proprietary pulsatile nitric oxide delivery.

INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide.

Field of Use
The clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases,  expanded the scope of the license from PH-IPF to PH in patients with Pulmonary Fibrosis (PH-PF), which includes idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, occupational and environmental lung disease, with a royalty on net sales of any commercial products for PH-PF.  Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred.

IPSCIO Record ID: 204327

License Grant
Swiss Licensor grants to Licensee, under the cystic fibrosis or CF Know-How and the CF Patent Rights
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product in North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product outside of the Territory and outside of North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export Other Products outside of the Territory and to make or have made or to purchase or have purchased Other Products for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export therapeutic products outside of the Field of Use and to make or have made or to purchase or have purchased therapeutic products outside the Field of Use for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export non-therapeutic products and to make or have made or to purchase or have purchased non-therapeutic products for such purposes.
License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.

IPSCIO Record ID: 26023

License Grant
This agreement between an Australian pharma and a pharmaceutical company based in Japan is for IP related to treatment for a fatal lung-scarring disease — idiopathic pulmonary fibrosis.
License Property
The drug is known as Esbriet or pirfenidone.

IPSCIO Record ID: 203566

License Grant
The parties entered into to a Research and Development Agreement dated March 10, 1997 relating to EPI-HNE4, an inhibitor of human neutrophil elastase.  The Parties now enter into this Agreement for thecommercialization of the results of the Research and Development Agreement.

Licensor grants the Swiss Licensee an exclusive license with the right to sublicense during the term of this Agreement, under the EPI-HNE Patent Rights, EPIHNE Technology, the cystic fibrosis or CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export CF Product in the Territory and to make or have made or to purchase or have purchased CF Product for such purposes.

Licensor grants exclusive license with the right to sublicense during the term of this Agreement, under the EPIHNE Patent Rights, EPI-HNE Technology, the applicable CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export any Other Product in the Territory and to make or have made or to purchase or have purchased such Other Products for such purposes.

License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.

IPSCIO Record ID: 285725

License Grant
The Institute, a not-for-profit corporation, granted Licensee an exclusive, worldwide license, with the right to grant sublicenses to non-affiliate third parties, to develop, make, have made, use, sell, offer for sale and import certain products for use in the field of fatty liver disease in humans receiving total parenteral nutrition, by administering, as monotherapy, a pharmaceutical composition comprising intravenous choline, wherein the fatty liver disease is selected from IFALD, non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, or non-alcoholic cirrhosis. Notwithstanding the exclusive rights granted to Licensee, the Institute shall retain the right to make, use and practice such patents in its own laboratories solely for non-commercial scientific purposes and for continued non-commercial research.
License Property
U.S. patent related to the treatment of fatty liver disease in humans.  The ucts are use in the field of fatty liver disease in humans receiving total parenteral nutrition, by administering, as monotherapy, a pharmaceutical composition comprising intravenous choline, wherein the fatty liver disease is selected from IFALD, non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, or non-alcoholic cirrhosis.
Field of Use
Fatty liver disease also known as hepatic steatosis, is a condition where excess fat builds up in the liver.  Fatty liver disease is very common with the incidence increasing with the obesity epidemic. Major risk factors include obesity and type 2 diabetes, though it's also associated with excessive alcohol consumption.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.